Safety and efficacy of azacitidine in elderly patients with intermediate to high-risk myelodysplastic syndromes

Por Navada, Shyamala C., Silverman, Lewis R.
Publicado no Ther Adv Hematol (2016)

Clinical development of demethylating agents in hematology

Por Navada, Shyamala C., Steinmann, Juliane, Lübbert, Michael, Silverman, Lewis R.
Publicado em 2014

JAK/STAT Pathways in Cytokine Signaling and Myeloproliferative Disorders: Approaches for Targeted Therapies

Por Jatiani, Shashidhar S., Baker, Stacey J., Silverman, Lewis R., Reddy, E. Premkumar
Publicado em 2010

Azacitidine in Lower‐Risk Myelodysplastic Syndromes: A Meta‐Analysis of Data from Prospective Studies

Por Komrokji, Rami, Swern, Arlene S., Grinblatt, David, Lyons, Roger M., Tobiasson, Magnus, Silverman, Lewis R., Sayar, Hamid, Vij, Ravi, Fliss, Albert, Tu, Nora, Sugrue, Mary M.
Publicado no Oncologist (2017)

Continued Azacitidine Therapy Beyond Time of First Response Improves Quality of Response in Patients With Higher-Risk Myelodysplastic Syndromes

Por Silverman, Lewis R., Fenaux, Pierre, Mufti, Ghulam J., Santini, Valeria, Hellström-Lindberg, Eva, Gattermann, Norbert, Sanz, Guillermo, List, Alan F., Gore, Steven D., Seymour, John F.
Publicado em 2011

Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine

Por Santini, Valeria, Fenaux, Pierre, Mufti, Ghulam J., Hellström-Lindberg, Eva, Silverman, Lewis R., List, Alan, Gore, Steven D., Seymour, John F., Backstrom, Jay, Beach, Charles L.
Publicado em 2010

Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best suppor...

Por Garcia-Manero, Guillermo, Almeida, Antonio, Giagounidis, Aristoteles, Platzbecker, Uwe, Garcia, Regina, Voso, Maria Teresa, Larsen, Stephen R., Valcarcel, David, Silverman, Lewis R., Skikne, Barry, Santini, Valeria
Publicado no BMC Hematol (2016)

A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care...

Por Gore, Steven D., Fenaux, Pierre, Santini, Valeria, Bennett, John M., Silverman, Lewis R., Seymour, John F., Hellström-Lindberg, Eva, Swern, Arlene S., Beach, Charles. L., List, Alan. F.
Publicado em 2013

Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial

Por Mesa, Ruben A., Silver, Richard T., Verstovsek, Srdan, Mascarenhas, John, Kessler, Craig M., Rondelli, Damiano, Goldberg, Judy D., Marchioli, Roberto, Demakos, Erin P., Silverman, Lewis R., Hoffman, Ronald
Publicado em 2013

Treatment of Myelodysplastic Syndrome with Two Schedules and Doses of Oral Topotecan: A Randomized Phase II Trial by the Cancer and Leukemia Group B (CALGB 19803)

Por Grinblatt, David L., Yu, Daohai, Hars, Vera, Vardiman, James W., Powell, Bayard L., Nattam, Sreenivasa, Silverman, Lewis R., de Castro, Carlos, Stone, Richard M., Bloomfield, Clara D., Larson, Richard A.
Publicado em 2009

Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes

Por Seymour, John F., Fenaux, Pierre, Silverman, Lewis R., Mufti, Ghulam J., Hellström-Lindberg, Eva, Santini, Valeria, List, Alan F., Gore, Steven D., Backstrom, Jay, McKenzie, David, Beach, C.L.
Publicado em 2010

Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leuke...

Por Medeiros, Bruno C., McCaul, Kelly, Kambhampati, Suman, Pollyea, Daniel A., Kumar, Rajat, Silverman, Lewis R., Kew, Andrea, Saini, Lalit, Beach, CL, Vij, Ravi, Wang, Xiwei, Zhong, Jim, Gale, Robert Peter
Publicado no Haematologica (2018)

Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best...

Por Nazha, Aziz, Sekeres, Mikkael A., Komrokji, Rami, Steensma, David P., Kantarjian, Hagop, Roboz, Gail, Fenaux, Pierre, Prebet, Thomas, Azarnia, Nozar, Zbyszewski, Patrick S., Fruchtman, Steven M., Santini, Valeria, Silverman, Lewis R., Platzbecker, Uwe, Garcia-Manero, Guillermo
Publicado no Blood Cancer J (2017)

Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies

Por Feld, Jonathan, Tremblay, Douglas, Dougherty, Mikaela, Czaplinska, Tina, Sanchez, Gillian, Brady, Claudia, Kremyanskaya, Marina, Bar-Natan, Michal, Keyzner, Alla, Marcellino, Bridget K., Gabrilove, Janice, Navada, Shyamala C., Silverman, Lewis R., El Jamal, Siraj M., Mascarenhas, John, Shih, Alan H.
Publicado no Hemasphere (2021)

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Por Fenaux, Pierre, Mufti, Ghulam J, Hellstrom-Lindberg, Eva, Santini, Valeria, Finelli, Carlo, Giagounidis, Aristoteles, Schoch, Robert, Gattermann, Norbert, Sanz, Guillermo, List, Alan, Gore, Steven D, Seymour, John F, Bennett, John M, Byrd, John, Backstrom, Jay, Zimmerman, Linda, McKenzie, David, Beach, C L, Silverman, Lewis R
Publicado em 2009

Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results

Por Heuser, Michael, Palmisiano, Neil, Mantzaris, Ioannis, Mims, Alice, DiNardo, Courtney, Silverman, Lewis R., Wang, Eunice S., Fiedler, Walter, Baldus, Claudia, Schwind, Sebastian, Pardee, Timothy, Perl, Alexander E., Cai, Charles, Kaulfuss, Stefan, Lagkadinou, Eleni, Rentzsch, Christine, Wagner, Markus, Wilkinson, Gary, Wu, Bingyan, Jeffers, Michael, Genvresse, Isabelle, Krämer, Alwin
Publicado no Leukemia (2020)

Phase I dose escalation study of lestaurtinib in patients with myelofibrosis

Por Hexner, Elizabeth O, Mascarenhas J, John, Prchal, Josef, Roboz, Gail J, Baer, Maria R, Ritchie, Ellen K, Leibowitz, David, Demakos, Erin P, Miller, Crystal, Siuty, James, Kleczko, Jill, Price, Leah, Jeschke, Grace, Weinberg, Rona, Basu T, Titiksha, Pahl, Heike L, Orazi, Attilio, Najfeld, Vesna, Marchioli, Roberto, Goldberg, Judith D, Silverman, Lewis R, Hoffman, Ronald
Publicado no Leuk Lymphoma (2015)

MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis

Por Rondelli, Damiano, Goldberg, Judith D., Isola, Luis, Price, Leah S., Shore, Tsiporah B., Boyer, Michael, Bacigalupo, Andrea, Rambaldi, Alessandro, Scarano, Marco, Klisovic, Rebecca B., Gupta, Vikas, Andreasson, Bjorn, Mascarenhas, John, Wetzler, Meir, Vannucchi, Alessandro M., Prchal, Josef T., Najfeld, Vesna, Orazi, Attilio, Weinberg, Rona S., Miller, Crystal, Barosi, Giovanni, Silverman, Lewis R., Prosperini, Giuseppe, Marchioli, Roberto, Hoffman, Ronald
Publicado em 2014

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies

Por Fandy, Tamer E., Herman, James G., Kerns, Patrick, Jiemjit, Anchalee, Sugar, Elizabeth A., Choi, Si-Ho, Yang, Allen S., Aucott, Timothy, Dauses, Tianna, Odchimar-Reissig, Rosalie, Licht, Jonathan, McConnell, Melanie J., Nasrallah, Chris, Kim, Marianne K. H., Zhang, Weijia, Sun, Yezou, Murgo, Anthony, Espinoza-Delgado, Igor, Oteiza, Katharine, Owoeye, Ibitayo, Silverman, Lewis R., Gore, Steven D., Carraway, Hetty E.
Publicado em 2009

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

Por Zeidan, Amer M, Boddu, Prajwal C, Patnaik, Mrinal M, Bewersdorf, Jan Philipp, Stahl, Maximilian, Rampal, Raajit K, Shallis, Rory, Steensma, David P, Savona, Michael R, Sekeres, Mikkael A, Roboz, Gail J, DeAngelo, Daniel J, Schuh, Andre C, Padron, Eric, Zeidner, Joshua F, Walter, Roland B, Onida, Francesco, Fathi, Amir, DeZern, Amy, Hobbs, Gabriela, Stein, Eytan M, Vyas, Paresh, Wei, Andrew H, Bowen, David T, Montesinos, Pau, Griffiths, Elizabeth A, Verma, Amit K, Keyzner, Alla, Bar-Natan, Michal, Navada, Shyamala C, Kremyanskaya, Marina, Goldberg, Aaron D, Al-Kali, Aref, Heaney, Mark L, Nazha, Aziz, Salman, Huda, Luger, Selina, Pratz, Keith W, Konig, Heiko, Komrokji, Rami, Deininger, Michael, Cirici, Blanca Xicoy, Bhatt, Vijaya Raj, Silverman, Lewis R, Erba, Harry P, Fenaux, Pierre, Platzbecker, Uwe, Santini, Valeria, Wang, Eunice S, Tallman, Martin S, Stone, Richard M, Mascarenhas, John
Publicado no Lancet Haematol (2020)